High doses of levofloxacin vs moxifloxacin against staphylococcal experimental foreign-body infection: the effect of higher MIC-related pharmacokinetic parameters on efficacy.

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Journal of Infection

• Publication date

  2009-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.jinf.2009.01.005PMID 19217166
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Efficacy of linezolid alone and in combination with rifampin in staphylococcal experimental foreign-body infection.

  2008cited by this paper
• Factors compromising the activity of moxifloxacin against intracellular Staphylococcus aureus.

  2007cited by this paper
• Mutant selection window hypothesis updated.

  2007cited by this paper
• Pharmacodynamic Evaluation of the Intracellular Activities of Antibiotics against Staphylococcus aureus in a Model of THP-1 Macrophages

  2006cited by this paper
• Efficacy of High Doses of Levofloxacin in Experimental Foreign-Body Infection by Methicillin-Susceptible Staphylococcus aureus

  2006influential reference
• The mutant selection window in rabbits infected with Staphylococcus aureus.

  2006cited by this paper
• Intrapulmonary pharmacokinetics and pharmacodynamics of high-dose levofloxacin in healthy volunteer subjects.

  2006cited by this paper
• Antistaphylococcal Effect Related to the Area under the Curve/MIC Ratio in an In Vitro Dynamic Model: Predicted Breakpoints versus Clinically Achievable Values for Seven Fluoroquinolones

  2005cited by this paper
• Antibiotics in laboratory medicine

  2005cited by this paper
• Quinolones in 2005: an update.

  2005cited by this paper
• Prosthetic-joint infections.

  2004cited by this paper
• In Vitro Pharmacodynamic Evaluation of the Mutant Selection Window Hypothesis Using Four Fluoroquinolones against Staphylococcus aureus

  2003cited by this paper
• AUC/MIC relationships to different endpoints of the antimicrobial effect: multiple-dose in vitro simulations with moxifloxacin and levofloxacin.

  2002cited by this paper
• Animal model pharmacokinetics and pharmacodynamics: a critical review.

  2002cited by this paper
• Comparison of Levofloxacin, Alatrofloxacin, and Vancomycin for Prophylaxis and Treatment of Experimental Foreign-Body-Associated Infection by Methicillin-Resistant Staphylococcus aureus

  2002cited by this paper
• Restricting the selection of antibiotic-resistant mutants: a general strategy derived from fluoroquinolone studies.

  2001cited by this paper
• Evaluation of the clinical microbiology profile of moxifloxacin.

  2001cited by this paper
• Pharmacodynamics of moxifloxacin and levofloxacin against Staphylococcus aureus and Staphylococcus epidermidis in an in vitro pharmacodynamic model.

  2001cited by this paper
• Does the dose matter?

  2001cited by this paper
• Safety and Pharmacokinetics of Multiple 750-Milligram Doses of Intravenous Levofloxacin in Healthy Volunteers

  2001cited by this paper
• Antibiotic resistance of bacteria in biofilms.

  2001cited by this paper
• Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically : approved standard

  2000cited by this paper
• Pharmacokinetics and Pharmacodynamics of Levofloxacin against Streptococcus pneumoniae and Staphylococcus aureus in Human Skin Blister Fluid

  2000cited by this paper
• Pharmacokinetics of a Once-Daily Oral Dose of Moxifloxacin (Bay 12-8039), a New Enantiomerically Pure 8-Methoxy Quinolone

  1999cited by this paper
• Bacterial biofilms: a common cause of persistent infections.

  1999cited by this paper
• Pharmacodynamic Evaluation of Factors Associated with the Development of Bacterial Resistance in Acutely Ill Patients during Therapy

  1998cited by this paper
• Role of rifampin for treatment of orthopedic implant-related staphylococcal infections: a randomized controlled trial. Foreign-Body Infection (FBI) Study Group.

  1998cited by this paper
• Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men.

  1998cited by this paper
• Pharmacokinetics, Safety, and Tolerability of Ascending Single Doses of Moxifloxacin, a New 8-Methoxy Quinolone, Administered to Healthy Subjects

  1998cited by this paper
• Comparison of the antibacterial activities of the quinolones Bay 12-8039, gatifloxacin (AM 1155), trovafloxacin, clinafloxacin, levofloxacin and ciprofloxacin.

  1997cited by this paper
• Oral treatment of Staphylococcus spp. infected orthopaedic implants with fusidic acid or ofloxacin in combination with rifampicin.

  1997cited by this paper
• In vivo verification of in vitro model of antibiotic treatment of device-related infection

  1995cited by this paper
• Pharmacokinetic and pharmacodynamic activities of ciprofloxacin against strains of Streptococcus pneumoniae, Staphylococcus aureus, and Pseudomonas aeruginosa for which MICs are similar

  1994cited by this paper
• New quinolones and gram-positive bacteria

  1994cited by this paper
• Microbiological tests to predict treatment outcome in experimental device-related infections due to Staphylococcus aureus.

  1994cited by this paper
• Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients

  1993cited by this paper
• Oral rifampin plus ofloxacin for treatment of Staphylococcus-infected orthopedic implants

  1993cited by this paper
• Antimicrobial treatment of orthopedic implant-related infections with rifampin combinations.

  1992cited by this paper
• Resistance of Staphylococcus aureus recovered from infected foreign body in vivo to killing by antimicrobials.

  1991cited by this paper
• The mode of action of quinolones: The paradox in activity of low and high concentrations and activity in the anaerobic environment

  1991cited by this paper
• Successful therapy of experimental chronic foreign-body infection due to methicillin-resistant Staphylococcus aureus by antimicrobial combinations

  1991cited by this paper
• Treatment of experimental foreign body infection caused by methicillin-resistant Staphylococcus aureus

  1990influential reference
• Correlation between in vivo and in vitro efficacy of antimicrobial agents against foreign body infections.

  1990cited by this paper
• Simultaneous comparison of three methods for assessing ceftazidime penetration into extravascular fluid

  1982cited by this paper
• Nalidixic Acid: an Antibacterial Paradox

  1975cited by this paper

• Current prospects of fluoroquinolones: pazufloxacin. A review

  2025cites this paper
• In vitro degradation, antibacterial activity and drug release of levofloxacin-loaded coatings on Mg alloy AZ31: The effect of chain length

  2024cites this paper
• Investigating the effect of some fluoroquinolones on C-reactive protein levels and ACh-Induced blood pressure reduction deviations after aging of diabetes in STZ-Induced diabetic wistar rats

  2020cites this paper
• Management of Periprosthetic Joint Infection

  2018cites this paper
• Oral antibiotic treatment of staphylococcal bone and joint infections in adults.

  2014cites this paper
• The effect of levofloxacin and moxifloxacin on cardiovascular functions of rats with streptozotocin-induced diabetes

  2013cites this paper
• Oral Agents for the Treatment of Orthopedic Infections Caused by Methicillin-resistant Staphylococci

  2011cites this paper